<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04256096</url>
  </required_header>
  <id_info>
    <org_study_id>17877519.6.1001.5327</org_study_id>
    <nct_id>NCT04256096</nct_id>
  </id_info>
  <brief_title>Randomization of Endovascular Treatment in Acute Ischemic Stroke in the Extended Time Window</brief_title>
  <acronym>RESILIENTExt</acronym>
  <official_title>Randomization of Endovascular Treatment With Stent-retriever and/or Thromboaspiration vs. Best Medical Therapy in Acute Ischemic Stroke Due to Large VEssel OcclusioN Trial in the Extended Time Window</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital das Clínicas de Ribeirão Preto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Geral de Fortaleza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Base</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundação Faculdade Regional de Medicina de São José do Rio Preto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UPECLIN HC FM Botucatu Unesp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Irmandade Santa Casa de Misericórdia de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidade Federal do Paraná</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Governador Celso Ramos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Estadual Central</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sao Jose do Avai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase III, randomized, multi-center, open label clinical trial that will examine whether
      endovascular treatment is superior to standard medical therapy alone in patients who suffer a
      large vessel anterior circulation ischemic stroke within 8-24 hours from time last seen well
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multi-center, randomized, controlled, open-label, blinded-endpoint trial with a
      sequential design. The randomization employs a 1:1 ratio of mechanical thrombectomy with
      stent-retriever and/or thromboaspiration versus medical management alone in patients who
      suffer a large vessel anterior circulation ischemic stroke between 8 and 24 hours from time
      last seen well. Randomization will be done under a minimization process using age (≤68 vs.
      &gt;68 years), baseline NIHSS (&lt;17 v. ≥17), ASPECTS (5-7 vs. 8-10), therapeutic window (6-12 or
      12-24 hours after TLKW), occlusion site (Intracranial ICA or M1), and clinical site. For the
      primary endpoint, subjects will be followed for 90 days post-randomization. Sham endovascular
      procedure has been rejected due to the medical risk of the angiography and practical issues
      that difficult to maintain blindness of investigators.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The randomization employs a 1:1 ratio of mechanical thrombectomy with stent-retriever and/or thromboaspiration versus medical management alone</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Sham endovascular procedure has been rejected due to the medical risk of the angiography and practical issues that difficult to maintain blindness of investigators. For the primary endpoint, subjects will be followed for 90 days post-randomization. Distribution of the modified Rankin Scale scores at 90 days will be evaluated by two separate assessors who are blinded to treatment. Primary Endpoint will consider central core lab readings only (video interview with RFA method) with local reading as a back-up mechanism.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale scores</measure>
    <time_frame>90 days</time_frame>
    <description>Distribution of the modified Rankin Scale scores at 90 days (shift analysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional independence</measure>
    <time_frame>90 days</time_frame>
    <description>Functional independence defined as mRS ≤2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disability on the utility-weighted modified Rankin scale (UW-mRS)</measure>
    <time_frame>90 days</time_frame>
    <description>Mean score for disability on the utility-weighted modified Rankin scale (UW-mRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EQ5D): EuroQol/EQ5D</measure>
    <time_frame>90 days, 1 year</time_frame>
    <description>Quality of life analysis as measured by EuroQol/EQ5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Mortality at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial Hemorrhage</measure>
    <time_frame>24 hours</time_frame>
    <description>Clinically significant ICH rates at 24 (-2/+12) hours. All intracerebral hemorrhages will be classified by a central core-lab using the Heidelberg criteria. Symptomatic ICH will be defined as per the SITS-MOST definition: deterioration in NIHSS score of ≥4 points within 24 hours from treatment and evidence of intraparenchymal hemorrhage type 2 in the 22 to 36 hours follow-up imaging scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural related complications</measure>
    <time_frame>immediately after procedure</time_frame>
    <description>Procedural related complications: arterial perforation, arterial dissection, and embolization in a previously uninvolved vascular territory</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">376</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>thrombectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mechanical thrombectomy with stent-retriever and/or thromboaspiration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best Medical treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thrombectomy</intervention_name>
    <description>Endovascular treatment of large vessel occlusion (mechanical thrombectomy) with stent-retriever and/or thromboaspiration (neurointerventionalist choice)</description>
    <arm_group_label>Clinical treatment</arm_group_label>
    <arm_group_label>thrombectomy</arm_group_label>
    <other_name>Endovascular treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute ischemic stroke where patient is ineligible for IV thrombolytic treatment or the
             treatment is contraindicated (e.g., subject presents beyond recommended time from
             symptom onset), or where patient has received IV thrombolytic therapy without clinical
             improvement.

          2. No significant pre-stroke functional disability (mRS ≤2)

          3. Baseline NIHSS score obtained prior to randomization must be equal or higher than 8
             points (assessed within one hour prior to qualifying imaging)

          4. Age ≥18 years (no upper age limit)

          5. Occlusion (TICI 0-1) of the intracranial ICA (distal ICA or T occlusions) and/or
             MCA-M1 segment suitable for endovascular treatment, as evidenced by CTA, MRA or
             angiogram, with or without concomitant cervical carotid occlusion or stenosis.

          6. The presence of Age-Adjusted modified Clinical ASPECTS Mismatch (mCAM) defined as
             ASPECTS 5-10 and one of the following criteria:

               1. NIHSS ≥ 8 and &gt;50% involvement in 0-1 Cortical (e.g. M1-6) ASPECTS areas (any
                  age);

               2. NIHSS ≥ 8 and &gt;50% involvement in 0-2 Cortical (e.g. M1-6) ASPECTS areas (and age
                  &lt; 80 years old);

               3. NIHSS ≥ 15 and &gt;50% involvement in 0-3 Cortical (e.g. M1-6) ASPECTS areas (and
                  age &lt; 80 years old).

          7. Patient treatable within 6-24 hours of symptom onset. Symptoms onset is defined as
             point in time the patient was last seen well (at baseline). Treatment start is defined
             as arterial puncture.

          8. Informed consent obtained from patient or acceptable patient surrogate

        Exclusion Criteria:

        -Clinical criteria

          1. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant
             therapy with INR &gt; 3.0

          2. Baseline platelet count &lt; 30.000/µL

          3. Baseline blood glucose of &lt; 50mg/dL

          4. Severe, sustained hypertension (SBP &gt; 185 mm Hg or DBP &gt; 110 mm Hg) NOTE: If the blood
             pressure can be successfully reduced and maintained at the acceptable level using AHA
             guidelines recommended medication (including iv antihypertensive drips), the patient
             can be enrolled.

          5. Patients in coma defined as totally unresponsive; responding only with reflexes or
             being areflexic (Intubated patients for transfer could be randomized only in case an
             NIHSS is obtained by a neurologist prior transportation).

          6. Seizures at stroke onset which would preclude obtaining a baseline NIHSS

          7. Serious, advanced, or terminal illness with anticipated life expectancy of less than
             one year.

          8. History of life-threatening allergy (more than rash) to contrast medium

          9. Subjects who has received IV t-PA treatment beyond 4.5 hours from the beginning of the
             symptoms

         10. Woman of childbearing potential who is known to be pregnant or who has a positive
             pregnancy test on admission.

         11. Subject participating in a study involving an investigational drug or device that
             would impact this study.

         12. Cerebral vasculitis

         13. Patients with a pre-existing neurological or psychiatric disease that would confound
             the neurological or functional evaluations, mRS score at baseline must be ≤2. This
             excludes patients who are severely demented, require constant assistance in a nursing
             home type setting or who live at home but are not fully independent in activities of
             daily living (toileting, dressing, eating, cooking and preparing meals, etc.)

         14. Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor
             from overseas).

             - Neuroimaging criteria

         15. Hypodensity on CT or restricted diffusion on MRI amounting to an ASPECTS score of &lt;5.

         16. Complete involvement of more than 3 cortical ASPECTS areas (e.g. M1, M2, M3, M4, M5,
             or M6).

         17. Complete absence of leptomeningeal collaterals on CT angiography (e.g. Malignant CTA
             pattern or score 0).

         18. CT or MR evidence of hemorrhage (the presence of GRE microbleeds is allowed).

         19. Significant mass effect with midline shift.

         20. Evidence of ipsilateral carotid occlusion, high grade stenosis or arterial dissection
             in the extracranial or petrous segment of the internal carotid artery that cannot be
             treated or will prevent access to the intracranial clot or excessive tortuosity of
             cervical vessels precluding device delivery/deployment

         21. Subjects with occlusions in multiple vascular territories (e.g., bilateral anterior
             circulation, or anterior/posterior circulation)

         22. Evidence of intracranial tumor (except small meningioma).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raul G Nogueira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheila CO Martins, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clinicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheila CO Martins, MD, PhD</last_name>
    <phone>51999628467</phone>
    <email>scmartins@hcpa.edu.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natacha Fleck</last_name>
    <phone>51992699829</phone>
    <email>pesquisaneurovascular@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Geral de Fortaleza</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceara</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabricio Lima, PhD</last_name>
      <phone>85999982150</phone>
      <email>fabricio.lima.neuro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Base</name>
      <address>
        <city>Brasília</city>
        <state>DF</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Leticia C Rebello, MD</last_name>
      <phone>61999150626</phone>
      <email>letirebello@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Associacao Congregacao de Santa Catarina</name>
      <address>
        <city>Vitória</city>
        <state>Espirito Santo</state>
        <zip>29050-335</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose A Fiorot Jr, PhD</last_name>
      <phone>27992778579</phone>
      <email>fiorotjr@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas da Universidade Federal do Paraná</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Viviane F Zetola</last_name>
      <phone>0154199761660</phone>
      <email>viviane.zetola@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Conferencia Sao jose do Avai</name>
      <address>
        <city>Itaperuna</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Ivete itaperuna P Goncalves</last_name>
      <phone>22988315201</phone>
      <email>ipilloster@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035007</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericordia de Porto Alegre - ISCMPA</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandre Maulaz</last_name>
      <phone>51992826915</phone>
      <email>maulaz@terra.com.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Governador Celso Ramos</name>
      <address>
        <city>Florianópolis</city>
        <state>SC</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Gladys L Martins, MD</last_name>
      <phone>48999831918</phone>
      <email>glentz63@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Botucatu</name>
      <address>
        <city>Botucatu</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Rodrigo Bazan, PhD</last_name>
      <phone>14981157727</phone>
      <email>bazan.r@terra.com.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas - UNICAMP</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabricio B Cardoso, MD</last_name>
      <phone>019981254952</phone>
      <email>fabriciobuchdid@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas de Ribeirao Preto</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Octavio M Pontes-Neto, PhD</last_name>
      <phone>16981013465</phone>
      <email>ompneto@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacao Faculdade Regional de Medicina S J Rio Preto</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Raquel Hidalgo, MD</last_name>
      <phone>17997640004</phone>
      <email>draquelhidalgo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de São Paulo - UNIFESP/EPM</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Gisele S Silva, PhD</last_name>
      <email>giselesampaio@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Clinicas de Porto Alegre</investigator_affiliation>
    <investigator_full_name>SHEILA CRISTINA OURIQUES MARTINS</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>ischemic stroke</keyword>
  <keyword>thrombectomy</keyword>
  <keyword>treatment</keyword>
  <keyword>acute stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Because of the sensitive nature of the data collected for this study, requests to access the dataset from qualified researchers trained in human subject confidentiality protocols may be sent to the principal investigators</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>after de publication for 6 months</ipd_time_frame>
    <ipd_access_criteria>Because of the sensitive nature of the data collected for this study, requests to access the dataset from qualified researchers trained in human subject confidentiality protocols may be sent to the principal investigators</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

